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Effect of vitamin E on lipid metabolism and atherosclerosis in [1, 2]. Several factors may contribute to the progression
ESRD patients. of atherosclerosis, including an increased prevalence of
Background. Oxidative stress is enhanced in patients with hypertension and diabetes. In addition, ESRD patientsend-stage renal disease (ESRD) undergoing hemodialysis
have an abnormal lipid profile characterized by reduced(HD). Bioincompatibility represents an important source of
high density lipoprotein (HDL)-cholesterol and moder-reactive oxygen species. HD patients exhibit altered anti-oxida-
tive defences and anti-oxidative vitamins such as vitamin E ate hypertriglyceridemia. However, these factors by
and C are altered in uremia. Frequently, HD patients also themselves are not sufficient to account for the high rate
suffer from atherosclerotic cardiac disease. We have previously of cardiovascular disease observed. Previous work onreported that low density lipoprotein (LDL) of HD patients
atherogenesis has focused on the importance of lipopro-is rich in malondialdehyde (MDA), an end product of lipid
tein oxidation within the arterial wall [3]. Oxidation ofperoxidation. MDA rich LDL is thought to be an atherogenic
lipoprotein due to its enhancement of macrophage foam cell low density lipoprotein (LDL) by free radicals is thought
formation. to contribute to the development of fatty plaques in the
Methods. We conducted a controlled study for two years walls of arteries, a condition known as atherosclerosis.comparing the effects of a vitamin E coated cellulose mem-
Data reported indicate that oxidative stress is likely tobrane dialyzer and an ordinary cellulose membrane dialyzer
occur in the blood of ESRD patients. Concentrations ofon lipid metabolism and the progress of atherosclerosis. LDL-
MDA and oxidized LDL (ox-LDL) were measured in HD malondialdehyde (MDA), a byproduct of lipid peroxida-
patients using these two types of dialyzers. Plasma vitamin tion, are increased in plasma and red blood cells of ESRD
E and lipid concentrations were also evaluated. The aortic patients [4]. In addition, concentrations of some antioxi-calcification index (ACI) was evaluated by CT scan to assess
dants are decreased [5]. A recent study by Maggi et althe progress of atherosclerosis before and for every year after
showed that in uremic patients, LDL appeared moretreatment.
Results. Use of a vitamin E coated cellulose membrane dia- susceptible to oxidation and that a prolonged dialytic
lyzer for six months, one year and two years resulted in a treatment caused a decrease in vitamin E concentrations
significant reduction in LDL-MDA and ox-LDL compared to in LDL [6]. We have shown that long-term (over 3 years)the ordinary cellulose membrane dialyzer. Treatment with a
administration of vitamin E to hemodialysis (HD) pa-vitamin E-coated dialyzer significantly reduced the percentage
tients decreased MDA concentrations in LDL and pre-increase in ACI after 24 months compared to the control. There
were no significant changes in plasma vitamin E and lipid vented aortic calcification, one of the markers of athero-
concentrations between the two groups. sclerosis, as detected by computed tomography [7].
Conclusions. These results suggest that the oxidative stress Recently, in an attempt to improve the biocompatibility
could be one of the stimulating factors of abnormal lipid metab-
of HD membrane, a new vitamin E-coated celluloseolism and atherosclerosis in ESRD patients.
membrane dialyzer was proposed [8]. This biomaterial
consists of a multilayer membrane modified on the blood
surface to support a coating of the liposoluble physiologi-End-stage renal disease (ESRD) patients often de-
cal antioxidant vitamin E and was reported to be highlyvelop atherosclerosis and, in addition, more than 50%
biocompatible and decrease polymorphonuclear cell ac-of these patients die from cardiovascular complications
tivation [9].
The present study was undertaken to investigate the
long-term effects of vitamin E-coated cellulose mem-Key words: end-stage renal disease, hemodialysis, oxidized LDL, ath-
erogenesis, anti-oxidant vitamins. brane dialyzer on lipid metabolism with respect to in
vivo LDL oxidation and the progress of atherosclerosis. 1999 by the International Society of Nephrology
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METHODS
The effects of two-year treatment with vitamin
E-coated cellulose membrane dialyzer on lipid metabo-
lism and atherosclerosis were studied in 50 stable HD
patients without diabetes mellitus. The patients were
randomly divided into two groups in order to match age
and sex. A group of 25 patients (11 men and 14 women,
age 57 6 8 years, period on HD 84.1 6 55.9 months)
underwent HD using a vitamin E-coated cellulose mem-
brane dialyzer (CL-E; Clirancet E, Terumo Corpora-
tion, Japan), and a group of 25 age- and sex-matched
patients (11 men and 14 women, age 58 6 10 years,
period on HD 88.2 6 65.2 months) underwent HD using
an ordinary regenerated cellulose membrane dialyzer
(Control). All patients were receiving treatment in the
dialysis unit of affiliated hospitals of Wakayama Medical
College. Laboratory determinations were carried out be-
fore and after every six months of treatment with the
CL-E or Control membrane. Aortic calcification index
(ACI) was evaluated by CT scan to assess the progress of
atherosclerosis before and for every year after treatment.
Heparinized blood samples were collected before and
after HD. LDL-MDA was determined by the thiobarbi-
Fig. 1. Pre-hemodialysis (HD; A) and post-HD (B) plasma low densityturic acid method and ox-LDL by Itabe et al’s ELISA lipoprotein-malondialdehyde (LDL-MDA) concentrations after treat-
method [10]. Plasma vitamin E and ACI were measured ment. Data are presented as mean 6 sd. Symbols are: (h) control;
( ) vitamin E coated cellulose membrane. *P , 0.01 vs. 0 (beforeas previously described [7]. Patients did not take vitamin
treatment).E or probucol for over one month prior to the start of
the study. All patients were informed of the purpose of
the study and gave their informed consent. The protocol
for this study was approved by the institutional review
board.
Statistical analysis
Results are expressed as mean 6 sd. Statistical ana-
lyzes were performed using Student’s t-test. The level of
statistical significance was defined as P , 0.05.
RESULTS
Figure 1 shows pre-HD and post-HD plasma LDL-
MDA concentrations after treatment with CL-E and
control membrane. CL-E treatment significantly reduced
post-HD plasma LDL-MDA concentrations after 18 and
24 months (P , 0.01, respectively). Figure 2 shows pre-
HD and post-HD plasma ox-LDL concentrations after
treatment with CL-E and control membrane. Pre-HD
plasma ox-LDL concentrations were significantly higher
in the control group at 24 months than before treatment
(P , 0.05). CL-E treatment significantly reduced post-
HD plasma ox-LDL concentrations after 6 and 18
Fig. 2. Pre-hemodialysis (HD; A) and post-HD (B) plasma oxidizedmonths (P , 0.05). Post-HD plasma ox-LDL concentra- low density lipoprotein (ox-LDL) concentrations after treatment. Data
tions after 6 and 18 months of treatment with CL-E were are presented as mean 6 sd. Symbols are: (h) control; ( ) vitamin E
coated cellulose membrane. *P , 0.05 vs. 0 (before treatment), **P ,significantly lower than in the control group (P , 0.05).
0.05 vs. control and 0 (before treatment).Figure 3 shows plasma vitamin E concentrations after
treatment. No significant differences were observed in
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reactions in the HD patients. In addition, CL-E treat-
ment significantly reduced the percentage increase in
ACI. These results are in agreement with our previous
study concerning the effects of oral administration of
vitamin E on the metabolism of LDL and aortic calcifi-
cation [4, 7]. Also, Galli et al reported that CL-E mem-
brane preserves blood antioxidants (particularly vitamin
E) and prevents lipoperoxidation both in vitro and in
vivo [9].
In the present study, we used two methods to estimate
the status of in vivo peroxidation of LDL, LDL-MDA
and ox-LDL. A method for measuring levels of MDA,
an end product of lipid peroxidation, has long been avail-
able, but it is indirect and nonspecific. Recently, ItabeFig. 3. Plasma vitamin E concentrations after treatment. Data are pre-
sented as mean 6 sd. Symbols are: (h) control; ( ) vitamin E coated et al have established and characterized a specific and
cellulose membrane. Differences between the two groups were not sensitive monoclonal antibody against human ox-LDL,
significant.
which has enabled us to measure circulating ox-LDL
levels using ELISA [10]. The fact that CL-E treatment
significantly reduced both plasma levels of LDL-MDA
and oxLDL strongly suggests that the CL-E membrane
is highly anti-oxidative.
The reason for the lack of significant differences in
plasma vitamin E concentrations between the control
and CL-E groups is unclear. However, as Galli et al
reported, the CL-E membrane may exert a site-specific
and timely scavenging function against oxygen free radi-
cals in synergy with a hypostimulatory effect on the poly-
morphonuclear cell respiratory burst [9].
In summary, CL-E treatment significantly reduced
plasma levels of LDL-MDA and ox-LDL in the HD
patients. In addition, CL-E treatment significantly re-
duced the percentage increase in ACI. These results
Fig. 4 Percent increase in aortic calcification index after treatment. suggest that CL-E treatment may be a promising inter-
Data are presented as mean 6 sd. Symbols are: (h) control; ( ) vention to prevent atherosclerosis in HD patients.
vitamin E coated cellulose membrane. *P , 0.02 vs. control.
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